English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/17963
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Título

Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine)

AutorPizarro, Nieves; Farré-Albaladejo, Magi; Pujadas, Mitona; Peiró, Ana María; Roset, Pere N.; Joglar Tamargo, Jesús; Torre, Rafael de la
Palabras clave3,4-Methylenedioxymethamphetamine
MDMA
Metabolites
3-methoxymethamphetamine
HMMA
Human samples
Elimination half-life
Fecha de publicaciónsep-2004
EditorAmerican Society for Pharmacology and Experimental Therapeutics
CitaciónDrug Metabolism and Disposition 32(9): 1001-1007 (2004)
Resumen3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a designer drug commonly misused in large segments of young populations. MDMA is usually formulated in tablets of its racemate (1:1 mixture of its enantiomers) in doses ranging from 50 to 200 mg. MDMA has an enantioselective metabolism, the (S)-enantiomer being metabolized faster than the (R)-enantiomer. Different pharmacologic properties have been attributed to each enantiomer. The carbon responsible for MDMA chirality is preserved along its metabolic disposition. An analytical method has been developed to determine MDMA enantiomers and those from its major metabolites, 3,4-methylenedioxyamphetamine (MDA), 3,4-dihydroxymeth-amphetamine (HHMA), and 4-hydroxy-3-methoxymethamphet-amine (HMMA). It has been applied to the analysis of plasma and urine samples from healthy recreational users of MDMA who participated voluntarily in a clinical trial and received 100 mg (R,S)-MDMA · HCl orally. (R)/(S) ratios both in plasma (0-48 h) and urine (0-72 h) for MDMA and MDA were >1 and <1, respectively. Ratios corresponding to HHMA and HMMA, close to unity, deviate from theoretical expectations and are most likely explained by the ability of MDMA to autoinhibit its own metabolism. The short elimination half-life of (S)-MDMA (4.8 h) is consistent with the subjective effects and psychomotor performance reported in subjects exposed to MDMA, whereas the much longer half-life of the (R)-enantiomer (14.8 h) correlates with mood and cognitive effects experienced on the next days after MDMA use.
Descripción7 pages, 2 figures, 2 tables.-- PMID: 15319342 [PubMed].
Versión del editorhttp://dmd.aspetjournals.org/cgi/content/abstract/32/9/1001
URIhttp://hdl.handle.net/10261/17963
ISSN0090-9556 (Print)
1521-009X (Online)
Aparece en las colecciones: (IQAC) Artículos
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Mostrar el registro completo
 


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.